BioLineRx Ltd. Director Avraham Molcho Stock Option Holdings Report

This SEC Form 3 filing reports the initial statement of beneficial ownership of securities by Avraham Molcho, a director of BioLineRx Ltd. The filing details Molcho's extensive stock option holdings granted under the company's 2003 Amended and Restated Share Incentive Plan. The report covers 10 different option grants dating from 2016 to 2024, with a total of 4,155,000 ordinary shares underlying the options. The options have various exercise prices ranging from $0.052 to $0.920 per share and expiration dates extending through 2034. The most recent grant from October 2024 includes 2,055,000 options, with 856,200 vested immediately and the remaining 1,198,800 vesting quarterly over 7 installments. All securities are held through a trustee to qualify for Israeli tax benefits under Section 102 of the Israeli Tax Ordinance.